Exenatide/Exenatide extended release + Dapagliflozin + Placebo
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Evaluate Ketogenic Stress
Conditions
Evaluate Ketogenic Stress
Trial Timeline
Nov 1, 2016 → Oct 24, 2021
NCT ID
NCT02962492About Exenatide/Exenatide extended release + Dapagliflozin + Placebo
Exenatide/Exenatide extended release + Dapagliflozin + Placebo is a pre-clinical stage product being developed by AstraZeneca for Evaluate Ketogenic Stress. The current trial status is completed. This product is registered under clinical trial identifier NCT02962492. Target conditions include Evaluate Ketogenic Stress.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02962492 | Pre-clinical | Completed |
Competing Products
3 competing products in Evaluate Ketogenic Stress
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| nirsevimab | AstraZeneca | Phase 1 | 33 |
| Denosumab | Amgen | Phase 3 | 76 |
| Afamelanotide | Clinuvel Pharmaceuticals | Phase 1 | 25 |